UBE4A Activators encompass a variety of chemical entities that specifically enhance the functional activity of UBE4A, a protein ubiquitously involved in the tagging of cellular proteins for degradation via the ubiquitin-proteasome system. These activators operate through distinct biochemical mechanisms that coalesce to amplify the activity of UBE4A, ensuring the timely and efficient regulation of protein turnover which is vital for maintaining cellular homeostasis. A prototypical class of these activators might include small molecules that stabilize the interaction between UBE4A and E1 activating enzymes, thus facilitating the initial step of ubiquitin activation. Another subset can potentially increase the affinity of UBE4A for E2 ubiquitin-conjugating enzymes, accelerating the transfer of ubiquitin from E2 to target substrates.
Additionally, certain UBE4A Activators may exert their effects by binding to allosteric sites on UBE4A, inducing conformational changes that enhance its catalytic efficiency. These allosteric modulators are particularly significant as they do not directly compete with substrates, thereby reducing the likelihood of off-target effects and increasing the specificity of activation. Further, some activators might selectively inhibit deubiquitinating enzymes (DUBs), which would indirectly increase the ubiquitin-mediated degradation of proteins by preventing the removal of ubiquitin tags once UBE4A has attached them to substrates. This intricate network of activation, facilitated by UBE4A Activators, ensures that proteins marked for degradation are swiftly and effectively processed, thus preserving cellular function and integrity. Collectively, these diverse yet specific mechanisms of action underscore the tailored approach by which UBE4A Activators enhance the protein's activity, reflecting the nuanced regulation required in ubiquitin-mediated proteolysis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride influences the Wnt signaling pathway by inhibiting GSK-3β, leading to the stabilization of β-catenin, which is known to interact with UBE4A in the proteasomal degradation process. This stabilization can indirectly enhance UBE4A's activity in ubiquitination. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can lead to the accumulation of ubiquitinated proteins, indirectly increasing the demand for UBE4A's ubiquitin ligase activity in the cell to tag proteins for degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a selective proteasome inhibitor; by preventing the degradation of ubiquitinated proteins, it could indirectly enhance the functional activity of UBE4A by increasing the cellular reliance on ubiquitination. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor similar to bortezomib, and it can also indirectly increase the functional activity of UBE4A by causing an accumulation of ubiquitinated proteins. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
PYR-41 is a ubiquitin-activating enzyme (E1) inhibitor, which could lead to an increased level of free ubiquitin in the cell. This increases the availability of ubiquitin for UBE4A-mediated ubiquitination processes. | ||||||
IU1 | 314245-33-5 | sc-361215 sc-361215A sc-361215B | 10 mg 50 mg 100 mg | $138.00 $607.00 $866.00 | 2 | |
IU1 is an inhibitor of the deubiquitinase USP14, which removes ubiquitin from proteins. Inhibiting USP14 can lead to an increased pool of ubiquitinated proteins, indirectly enhancing the activity of UBE4A in the ubiquitin-proteasome pathway. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide promotes the degradation of several transcription factors via the ubiquitin-proteasome system. Its effect on increasing proteasomal degradation can indirectly enhance UBE4A's ubiquitination activity. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, leading to ER stress and the unfolded protein response, which may increase the demand for UBE4A's activity in tagging misfolded proteins for degradation. | ||||||